012790.KQ Sinil Pharmaceutical Co. Ltd

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
6,090 KRW
Close of Oct 31, 2026
4,820 6,640
Market cap
KRW 70.4B
P/E
11.3x
P/B
0.46x
ROE
4.8%
Dividend yield
3.12%
Fundamental score
2.7/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 012790.KQ undervalued?

Graham number
Price6,090
Graham value12,708
Discount52.1%

012790.KQ trades 52.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sinil Pharmaceutical Co. Ltd fundamental analysis

13 of 22 checks passed

ROE 0/2

Low return on equity (4.8%), below 10%.

ROA 1/1

Return on assets (4.2%) is above the industry median (1.4%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-47.3%) is not above the 5-year average (-0.8% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-47.3%) is below the industry median (1.8%).

Revenue Growth 1/2

Revenue grew 0.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 588.5x against interest expense, well covered.

PE vs Market 0/1

PE (11.3x) is above the market median (11.3x).

PE vs Industry 1/1

PE (11.3x) is below the industry median (11.4x).

PBV 1/1

Price to book (0.5x) is below the industry median (0.9x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 5.2, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (3.1%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 29.2%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Sinil Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sinil Pharmaceutical Co. Ltd

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin su…

Full company profile